These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 28277867)

  • 1. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different.
    Cheng AYY; Patel DK; Reid TS; Wyne K
    Adv Ther; 2019 May; 36(5):1018-1030. PubMed ID: 30929185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.
    Yamamoto C; Miyoshi H; Fujiwara Y; Kameda R; Ichiyama M; Nomoto H; Kameda H; Nakamura A; Atsumi T
    Endocr J; 2016; 63(1):53-60. PubMed ID: 26522272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
    Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
    Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
    Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
    J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study.
    Lualdi C; Silverii A; Dicembrini I; Pala L; Monami M; Mannucci E
    J Endocrinol Invest; 2019 Mar; 42(3):319-326. PubMed ID: 29987755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycemia rates with basal insulin analogs.
    Little S; Shaw J; Home P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?
    Wallace JP; Wallace JL; McFarland MS
    Ann Pharmacother; 2014 Mar; 48(3):361-8. PubMed ID: 24396092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K
    Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin glargine in the treatment of type 1 and type 2 diabetes.
    Barnett AH
    Vasc Health Risk Manag; 2006; 2(1):59-67. PubMed ID: 17319470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
    Owens DR; Bolli GB
    Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.
    Vargas-Uricoechea H
    J Diabetes Res; 2018; 2018():2052101. PubMed ID: 29619381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
    Duckworth W; Davis SN
    J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New generation of insulins: glargine U300. Summary of clinical evidence].
    Musso C; Capurro L; Mingote E; Forti L; Guaita MS
    Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.